Antiarrhythmic Agents Flashcards

(33 cards)

1
Q

What are the 5 phases of the Action Potential of the Cardiac Muscle Cell?

A

Phase 0: Sodium ions move INTO cells (depolarization)
Phase 1: Potassium ions move OUT of cells
Phase 2: Calcium ions move INTO cells (plateau stage)
Phase 3: MORE Potassium ions move OUT of cells (repolarization)
Phase 4: Back at rest and ready to start again

Summit Sodium (DEpolarization)
Plummet Potassium (REpolarization)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What are some causes of Cardiac Arrhythmias?

A
  • Electrolyte imbalances that alter the action potential
  • Decrease in oxygen delivered to the cells
  • Structural damage that changes the conduction pathway through the heart
  • Acidosis or accumulation of waste products that alter the action potential
  • Drugs that alter the action potential or cardiac conduction
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

How do the classifications of Antiarrhythmics work?

A

Class I: Block sodium channels
Class II: Act on autonomic receptors
Class III: Block potassium channels
Class IV: Block calcium channels

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Lifespan considerations of Antiarrhythmics
In Children

A
  • More likely to experience Adverse effects
  • Digoxin IS approved in children
  • Doses are calculated by age and weight
  • Ablation procedures can be successful as alternative to drug therapy
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Lifespan considerations of Antiarrhythmics
In Adults

A
  • Used frequently during emergencies
  • Monitor frequently
  • Avoid use in pregnancy and lactation (alternative feeding method needed)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Lifespan considerations of Antiarrhythmics
In Older Adults

A
  • Frequently prescribed
  • More likely to experience adverse effects
  • Start low
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Class I Antiarrhythmics
Sub-Classes and Drug Names

A
  • Ia: Procainamide, quinidine
  • Ib: Lidocaine
  • Ic: Flecainide, propafenone
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Class I Antiarrhythmics
Mechanism of Action

A
  • Block the sodium channels in the cell membrane during Phase 0 of the action potential
  • Decreases depolarization
  • Decreases automaticity of ventricular cells
  • Increases ventricular fibrillation threshold
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Class I Antiarrhythmics
Indications

A
  • Tachycardia
  • Life-threatening ventricular arrythmias
  • Symptomatic paroxysmal atrial arrhythmias
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Class I Antiarrhythmics
Contraindications

A

Absolute:
* Allergy
* Bradycardia, heart block
* CHF
* Hypotension, shock
* Electrolyte disturbances

Cautions:
* Renal or hepatic dysfunction
* Pregnancy or lactation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Class I Antiarrhythmics
Adverse Effects

A

Due to delayed action potential of all cells
* CNS: dizziness, fatigue, slurred speech
* GI: Nausea and vomiting
* CV: Arrhythmias, heart block, hypotension, vasodilation, cardiac arrest
* Respiratory depression
* Misc.: rash, loss of hair, potential bone marrow suppression

Procainamide: fever, hepatomegaly, neutropenia, painful joints, liver failure, pericarditis, hemolytic anemia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Class I Antiarrhythmics
Drug Interactions

A

Numerous
ie. Cemetidine, Digoxin, warfarin

Food:
Quinidine: foods that alkanalize the urine (citrus juice, vegetables, antacids, milik products); grapefruit juice

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Class II Antiarrhythmics
Mechanism of Action

A
  • “-olol”s: Beta-adrenergic blockers block beta receptors, causing a depression of Phase 4 of the action potential (rest phase)
  • Digoxin and Adenosine act on the autonomic nervous system
  • Competitively block beta receptors in the heart and kidneys
  • Decrease HR, cardiac excitability, and cardiac output
  • Slow conduction through the AV node
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Class II Antiarrhythmics
Indications

A
  • Rapid atrial fibrillation
  • Atrial flutter
  • Paroxysmal SVT
  • PVCs
  • Ventricular tachycardia

Adenosine is used for SVT when other measures are not effective - it is quick acting and short lasting

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Class II Antiarrhythmics
Drug Names

A

Acebutolol
Esmolol
Propranolol

Digoxin
Adenosine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Class II Antiarrhythmics
Contraindications

A

Absolute:
* Allergy
* Sinus bradycardia
* AV block
* Cardiogenic shock
* Respiratory Depression

Caution:
* Diabetes
* Thyroid dysfunction
* Asthma or COPD
* Pregnancy and lactation
* Renal and hepatic dysfunction

17
Q

Class II Antiarrhythmics
Adverse Effects

A
  • CNS: Dizziness, insomnia, dreams, fatigue
  • CV: hypotension, bradycardia, AV block, arrhythmias
  • Respiratory: Bronchospasm, dyspnea
  • GI: Nausea, vomiting, anorexia
18
Q

Class II Antiarrhythmics
Drug Interactions

A
  • Verapamil or diltiazem (increased risk of CV effects)
  • Antidiabetic medications
  • Methylxanthines
19
Q

Class III Antiarrhythmics
Mechanism of Action

A
  • Block potassium channels and slow outward movement of potassium during Phase 3 of the action potential (prolonging it)
20
Q

Class III Antiarrhythmics
Indications

A
  • Life-threatening ventricular arrhythmias
  • Maintenance of sinus rhythm after conversion of atrial arrhythmias
21
Q

Class III Antiarrhythmics
Contraindications

A

Absolute:
* When used for life threatening arrhythmias - there is NO contraindication
* When used for NON-life threatening arrhythmias: bradyarrhythmias

Cautions:
* Shock, hypotension
* Respiratory depression
* Prolonged QT interval
* Renal or hepatic disease
* Amiodarone: thyroid or pulmonary disease

22
Q

Class III Antiarrhythmics
Drug Names

A

Sotalol
Amiodarone
Dofetilide
(SAD)

23
Q

Class III Antiarrhythmics
Adverse Effects

A
  • GI: Nausea and vomiting
  • CNS: dizziness, weakness
  • CV: hypotension, arrhythmia
24
Q

Class III Antiarrhythmics
Drug Interactions

A

Numerous
ie.
Digoxin, quinodine, antihistamines, TCAs, phenothiazines

25
**Class IV Antiarrhythmics** Mechanism of Action
* Block the movement of **calcium ions** across the cell membrane, depressing the generation of action potentials and **delaying phases 1 and 2** of repolarization * Slows conduction through the AV node
26
**Class IV Antiarrhythmics** Drug Names
**Diltiazem** **Verapamil** *(Calcium Channel Blockers)*
27
**Class IV Antiarrhythmics** Indications
* Rapid supraventricular dysrhythmias *(rapid afib, atrial flutter, paroxysmal supraventricular tachycardia)*
28
**Class IV Antiarrhythmics** Contraindications
**Absolute:** * Allergy * Sick Sinus Syndrome * Heart Block * CHF * Hypotension **Caution:** * Idiopathic hypertrophic subaortic stenosis *(extra thick heart muscle)* * Pregnancy and lactation * Renal and hepatic impairment
29
**Class IV Antiarrhythmics** Adverse Effects
* **CNS:** dizziness, weakness, fatigue, depression * **GI:** upset * **CV:** hypotension, CHF, shock, edema
30
**Class IV Antiarrhythmics** Drug Interactions
**Numerous** ie. Beta Blockers Digoxin
31
**Antiarrhythmic Therapy** Assessment
* Assess for contraindications and cautions * CNS: level of alertness, speech and vision, reflexes * CV: pulse, BP, HR, rhythm, heart sounds, cardiac monitoring, baseline ECG * Respiratory: rate and depth, lung sounds * Abdomen: bowel sounds * Skin: color, lesions, temperature **Labs:** * CBC * Renal and liver function tests
32
**Antiarrhythmic Therapy** Nursing Diagnoses/Conclusions
* Altered cardiac output *(r/t cardiac effects)* * Altered sensory perception *(r/t CNS effects)* * Injury risk *(r/t adverse effects)* * Knowledge deficit
33
**Antiarrhythmic Therapy** Implementation/Patient Teaching
* Titrate the dose to the smallest amount needed to achieve control of the arrhythmia * Continually monitor cardiac rhythm when starting or changing dose * Ensure that emergency life support equipment is readily available * Administer parenteral forms only if oral form is not feasible * Reduce dose in pts. with renal or hepatic dysfunction * Safety precautions: side rails, lighting, noise control * Periodic monitoring for long term therapy